Redenlab partners with BDCRC to support new NIH-funded Batten disease research
A newly formed research network focused on Batten disease, a rare and inherited brain disorder that primarily affects…
Speech
Latest content
Redenlab awarded $2.5M to scale AI-driven speech biomarkers for dementia detection
Receiving the CUREator+ Dementia & Cognitive Decline funding marks a meaningful milestone in our journey to transform how…
Redenlab announces landmark study in collaboration with Queensland Institute of Medical Research
Redenlab announces landmark study in collaboration with Queensland Institute of Medical Research
People Who Stutter Create (PWSC) presents “Stuttering Can Create Time” as part of the Whitney Biennial 2024
Displayed at 95 Horatio Street, NY, PWSC argues that stuttering fosters deep listening and collaboration, aiming to transform…
Redenlab’s Chief Science Officer, Adam P. Vogel, PhD, leads groundbreaking study on speech analysis for neurodegenerative diseases
MEDIA RELEASE Melbourne, 19 January 2024 — Redenlab, a leader in innovative healthcare solutions, ispleased to announce a…
Childhood apraxia of speech clinical trial
Speech disorders impacting children have debilitating impacts on educational, social and later employment outcomes. There are limited therapeutic…
Researchers working towards finding a new treatment for Spinocerebellar Ataxia Type 1 (SCA1)
Spinocerebellar ataxia Type 1 (SCA1) is a dominantly inherited neurodegenerative disease resulting in balance, speech, thinking and coordination…
The FA App
Friedreich ataxia (FA) is a progressive, genetically inherited multisystem disease that affects children and adults. FA leads to…
TRACK-FA Study
Friedreich ataxia (FA) is an inherited, multisystem neurodegenerative disease that results in profound changes to speech, swallowing, balance,…
Professor Angela Morgan leads the Translational Centre for Speech Disorders in groundbreaking NHMRC CRE research program
Redenlab, a leading provider of innovative solutions in the field of pediatric and neurodevelopment communication, proudly announces that…
Academic and patient advocacy group collaborations in Dentatorubral-pallidoluysian atrophy (DRPLA)
Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare progressive brain disorder that can impact children and adults. In children, DRPLA…
Redenlab shines in Huberman Podcast, unveiling cannabis study and speech analysis expertise
MEDIA RELEASERedenlab, a leading techbio company, proudly announces its recent feature on the highly acclaimed Huberman Podcast. The…
Redenlab selected for world-first international collaboration investigating neurofilament light chain and voice for diagnosing dementia
Redenlab are partnering with Monash university, University of Melbourne, Eastern Health, and Invicta to deliver this world-first collaboration…
The L16HTHOUSE Study
L16HTHOUSE is a research trial testing an experimental medication for treating speech, motor, learning, and other developmental delays…
Temporary Assessment of Language in Kabuki Syndrome (TALK) Study
Speech and language development is a complex, multifactorial process driven by the individual’s ability to process and formulate…
ARIAS: Zooming in on eye-based biomarkers for Alzheimer’s
Scientists are turning to retinas as a potential screening target for early signs of Alzheimer’s, an incurable neurodegenerative…
Redenlab working as industry partner supporting a successful Australian Research Council Training Centre for Optimal Ageing
Redenlab are part of a successful consortium securing funding for training a new cohort of early career researchers…
How important is stability in your speech measures?
In our new study, published in the Journal of Acoustical Society of America, we tested reliability, stability, and…
Exploring the speech and language of individuals with non‐syndromic submucous cleft palate: a preliminary report
BackgroundSubmucous cleft palate (SMCP) has a heterogeneous presentation and is often identified late or misdiagnosed. Diagnosis is prompted…
Redenlab sign contract with Koneksa Health & Takeda Pharmaceuticals
Redenlab are partnering with Koneksa Health to provide speech testing to Takeda Pharmaceuticals USA on a multi-site trial…
